CHRS Coherus BioSciences, Inc.

22.50
-0.5  -2.17%
Previous Close 23.00
Open 22.90
Price To book 30.54
Market Cap 982.17M
Shares 43,652,000
Volume 409,713
Short Ratio 13.83
Av. Daily Volume 355,534

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due 1H 2017.
CHS-1420
Psoriasis
PDUFA date June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. Coherus BioSciences to Report Fourth Quarter and Full Year 2016 Financial Results on March 13th
  2. Coherus BioSciences Announces New Employment Inducement Grants
  3. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
  4. Why Coherus Biosciences Is Falling Today
  5. Coherus Biosciences Inc (CHRS) Could Be A Discount Entry On The Pullback
  6. Coherus Prices Public Offering of Common Stock
  7. Coherus Announces Proposed Public Offering of Common Stock
  8. COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  9. Coherus BioSciences Files Four Petitions for Inter Partes Review Against AbbVie’s HUMIRA® Formulation Patent 9,085,619
  10. Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : January 27, 2017
  11. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : January 26, 2017
  12. ETFs with exposure to Coherus BioSciences, Inc. : January 19, 2017
  13. Coherus Offers Positive Phase III Data on Humira Biosimilar
  14. Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
  15. Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : January 10, 2017
  16. Coherus BioSciences Management to Present at The 35th Annual J.P. Morgan Healthcare Conference
  17. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 19, 2016
  18. Coherus BioSciences to Present at BMO – Prescriptions for Success Healthcare Conference on December 14th
  19. Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : December 7, 2016
  20. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : December 6, 2016